Eczema Free Forever™ Eczema Free Forever™

EU approves Sanofi and Regeneron’s dupilumab in eczema – Reuters


Reuters
EU approves Sanofi and Regeneron's dupilumab in eczema
Reuters
Atopic dermatitis is a chronic type of skin inflammation also known as eczema, which in severe cases causes constant, and often unbearable, itching. A human monoclonal antibody, Dupixent is designed to specifically inhibit two key proteins which are …
Sanofi's Dupixent gets Europe eczema nodPharmaTimes
Sanofi, Regeneron claim EU approval for eczema drug DupixentPMLiVE
Regeneron and Sanofi Announce Approval of DUPIXENT® (dupilumab) to Treat Adult Patients with Moderate-to …Markets Insider
pharmaphorum
all 7 news articles »

eczema – Google News

AbbVie’s positive eczema study drags down Regeneron’s shares – Reuters


Reuters
AbbVie's positive eczema study drags down Regeneron's shares
Reuters
AbbVie Inc said on Thursday its experimental drug to treat adults with moderate-to-severe eczema met the main goal in a mid-stage study, dragging down …
AbbVie Inc (ABBV) Stock Surges on Positive Eczema StudyInvestorplace.com
AbbVie shares rally on positive eczema study, competitor Regeneron dropsInvesting.com
How AbbVie Could Chip Away At Regeneron's Potential BlockbusterInvestor’s Business Daily
Proactive Investors UK –Zacks Investment Research
all 144 news articles »

eczema – Google News